Recursion

Recursion uses cellular imaging data and AI through their Recursion Operating System platform to understand biological disruptions driving disease and accelerate drug discovery with improved speed, efficiency, and reduced costs.

Company was founded over a decade ago and has demonstrated significant improvements in speed, efficiency, and reduced costs from hit identification to IND-enabling studies compared to traditional pharmaceutical companies. They have dosed their first patient in Phase 1 clinical study of REC-3565 and reported positive Phase 1b/2 results from REC-4881 TUPELO trial.